{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T02:36:16Z","timestamp":1793500576922,"version":"4.5.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,10,11]],"date-time":"2022-10-11T00:00:00Z","timestamp":1665446400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,10,11]],"date-time":"2022-10-11T00:00:00Z","timestamp":1665446400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100014269","name":"Philippe Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014269","id-type":"DOI","asserted-by":"publisher"}]},{"name":"French Fonds de Recherche en Sant\u00e9 Respiratoire et Fondation du Souffle : Bourse de Mobilit\u00e9 Juliette Ostinelli, AstraZeneca, Coll\u00e8ge des Enseignants de Pneumologie.","id":[{"id":"https:\/\/ror.org\/04qdyps56","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Division of Intramural Research, NIAID, NIH"},{"name":"Foch Foundation"},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Respir Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Anti GM-CSF autoantibodies (aAb) have been related to acquired pulmonary alveolar proteinosis (PAP) and described in cases of severe infections such as cryptococcosis and nocardiosis in previously healthy subjects. Whether there are different anti-GM-CSF autoantibodies corresponding to these phenotypes is unclear. Therefore, we examined anti-GM-CSF autoantibodies to determine whether amount or neutralizing activity could distinguish between groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Plasma samples gathered in the National Institute of Health from patients with anti GM-CSF aAb and either PAP (n\u2009=\u200915), cryptococcal meningitis (n\u2009=\u200915), severe nocardiosis (n\u2009=\u20095) or overlapping phenotypes (n\u2009=\u20096) were compared. The relative amount of aAb was assessed using a particle-based approach, reported as a mouse monoclonal anti-human GM-CSF as standard curve and expressed in an arbitrary Mouse Monoclonal Antibody Unit (MMAU). The neutralizing activity of the plasma was assessed by inhibition of GM-CSF-induced intracellular phospho-STAT5 (pSTAT5) in monocytes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Anti-GM-CSF aAb relative amounts were higher in PAP patients compared to those with cryptococcosis (mean 495\u2009\u00b1\u2009464 MMAU\n                      <jats:italic>vs<\/jats:italic>\n                      197\u2009\u00b1\u2009159 MMAU,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.02); there was no difference with patients with nocardiosis (430\u2009\u00b1\u2009493 MMAU) nor between the two types of infections.\n                    <\/jats:p>\n                    <jats:p>\n                      The dilution of plasma resulting in 50% inhibition of GM-CSF-induced pSTAT5 (approximate IC\n                      <jats:sub>50<\/jats:sub>\n                      ) did not vary appreciably across groups of patients (1.6\u2009\u00b1\u20093.1%, 3.9\u2009\u00b1\u20096% and 1.8\u2009\u00b1\u20092.2% in PAP patients, cryptococcosis and nocardiosis patients, respectively). Nor was the concentration of GM-CSF necessary to induce 50% of maximal GM-CSF-induced pSTAT5 in the presence of 10 MMAU of anti-GM-CSF aAb (EC\n                      <jats:sub>50<\/jats:sub>\n                      ). When studying longitudinal samples from patients with PAP or disseminated nocardiosis, the neutralizing effect of anti-GM-CSF aAb was relatively constant over time despite targeted treatments and variations in aAb levels.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Despite different clinical manifestations, anti-GM-CSF antibodies were similar across PAP, cryptococcosis and nocardiosis. Underlying host genetics and functional analyses may help further differentiate the biology of these conditions.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12931-022-02103-9","type":"journal-article","created":{"date-parts":[[2022,10,11]],"date-time":"2022-10-11T06:03:11Z","timestamp":1665468191000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Neutralizing GM-CSF autoantibodies in pulmonary alveolar proteinosis, cryptococcal meningitis and severe nocardiosis"],"prefix":"10.1186","volume":"23","author":[{"given":"H\u00e9l\u00e8ne","family":"Salvator","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aristine","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsey B.","family":"Rosen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter R.","family":"Williamson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John E.","family":"Bennett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anuj.","family":"Kashyap","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyung J.","family":"Kwon-Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ho","family":"Namkoong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christa S.","family":"Zerbe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven M.","family":"Holland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,10,11]]},"reference":[{"key":"2103_CR1","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1146\/annurev-immunol-032713-120222","volume":"32","author":"SK Browne","year":"2014","unstructured":"Browne SK. Anticytokine autoantibody-associated immunodeficiency. Annu Rev Immunol. 2014;32:635\u201357.","journal-title":"Annu Rev Immunol"},{"key":"2103_CR2","doi-asserted-by":"publisher","DOI":"10.1126\/science.abd4585","author":"P Bastard","year":"2020","unstructured":"Bastard P, Rosen LB, Zhang Q, Michailidis E, Hoffmann H-H, Zhang Y, et al. Auto-antibodies against type I IFNs in patients with life-threatening COVID-19. Science. 2020. https:\/\/doi.org\/10.1126\/science.abd4585.","journal-title":"Science"},{"issue":"7","key":"2103_CR3","first-page":"4769","volume":"175","author":"SY Patel","year":"2005","unstructured":"Patel SY, Ding L, Brown MR, Lantz L, Gay T, Cohen S, et al. Anti-IFN-gamma autoantibodies in disseminated nontuberculous mycobacterial infections. J Immunol Baltim Md. 2005;175(7):4769\u201376.","journal-title":"J Immunol Baltim Md."},{"issue":"1","key":"2103_CR4","doi-asserted-by":"publisher","first-page":"e10","DOI":"10.1086\/380453","volume":"38","author":"R D\u00f6ffinger","year":"2004","unstructured":"D\u00f6ffinger R, Helbert MR, Barcenas-Morales G, Yang K, Dupuis S, Ceron-Gutierrez L, et al. Autoantibodies to interferon-gamma in a patient with selective susceptibility to mycobacterial infection and organ-specific autoimmunity. Clin Infect Dis Off Publ Infect Dis Soc Am. 2004;38(1):e10-14.","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am."},{"issue":"2","key":"2103_CR5","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1084\/jem.20091983","volume":"207","author":"A Puel","year":"2010","unstructured":"Puel A, D\u00f6ffinger R, Natividad A, Chrabieh M, Barcenas-Morales G, Picard C, et al. Autoantibodies against IL-17A, IL-17F, and IL-22 in patients with chronic mucocutaneous candidiasis and autoimmune polyendocrine syndrome type I. J Exp Med. 2010;207(2):291\u20137.","journal-title":"J Exp Med"},{"key":"2103_CR6","doi-asserted-by":"publisher","first-page":"6526","DOI":"10.1126\/science.aay5731","volume":"371","author":"TJ Break","year":"2021","unstructured":"Break TJ, Oikonomou V, Dutzan N, Desai JV, Swidergall M, Freiwald T, et al. Aberrant type 1 immunity drives susceptibility to mucosal fungal infections. Science. 2021;371:6526.","journal-title":"Science"},{"issue":"6\u20137","key":"2103_CR7","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1007\/s00439-020-02180-0","volume":"139","author":"C-L Ku","year":"2020","unstructured":"Ku C-L, Chi C-Y, von Bernuth H, Doffinger R. Autoantibodies against cytokines: phenocopies of primary immunodeficiencies? Hum Genet juin. 2020;139(6\u20137):783\u201394.","journal-title":"Hum Genet juin"},{"key":"2103_CR8","doi-asserted-by":"crossref","unstructured":"Kitamura T, Tanaka N, Watanabe J, Uchida, Kanegasaki S, Yamada Y, et al. Idiopathic pulmonary alveolar proteinosis as an autoimmune disease with neutralizing antibody against granulocyte\/macrophage colony-stimulating factor. J Exp Med. 1999;190(6):875\u201180.","DOI":"10.1084\/jem.190.6.875"},{"issue":"4","key":"2103_CR9","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1016\/j.immuni.2019.03.022","volume":"50","author":"M Dougan","year":"2019","unstructured":"Dougan M, Dranoff G, Dougan SK. GM-CSF, IL-3, and IL-5 family of cytokines: regulators of inflammation. Immunity. 2019;50(4):796\u2013811.","journal-title":"Immunity"},{"issue":"1","key":"2103_CR10","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/s41572-019-0066-3","volume":"5","author":"BC Trapnell","year":"2019","unstructured":"Trapnell BC, Nakata K, Bonella F, Campo I, Griese M, Hamilton J, et al. Pulmonary alveolar proteinosis. Nat Rev Dis Primer. 2019;5(1):16.","journal-title":"Nat Rev Dis Primer"},{"issue":"8","key":"2103_CR11","first-page":"3959","volume":"190","author":"LB Rosen","year":"2013","unstructured":"Rosen LB, Freeman AF, Yang LM, Jutivorakool K, Olivier KN, Angkasekwinai N, et al. Anti-GM-CSF autoantibodies in patients with cryptococcal meningitis. J Immunol Baltim Md 1950. 2013;190(8):3959\u201366.","journal-title":"J Immunol Baltim Md 1950."},{"issue":"7","key":"2103_CR12","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1093\/cid\/ciu968","volume":"60","author":"LB Rosen","year":"2015","unstructured":"Rosen LB, Rocha Pereira N, Figueiredo C, Fiske LC, Ressner RA, Hong JC, et al. Nocardia-induced granulocyte macrophage colony-stimulating factor is neutralized by autoantibodies in disseminated\/extrapulmonary nocardiosis. Clin Infect Dis. 2015;60(7):1017\u201325.","journal-title":"Clin Infect Dis"},{"issue":"2","key":"2103_CR13","doi-asserted-by":"publisher","first-page":"e00912","DOI":"10.1128\/mBio.00912-14","volume":"5","author":"T Saijo","year":"2014","unstructured":"Saijo T, Chen J, Chen SC-A, Rosen LB, Yi J, Sorrell TC, et al. Anti-granulocyte-macrophage colony-stimulating factor autoantibodies are a risk factor for central nervous system infection by Cryptococcus gattii in otherwise immunocompetent patients. MBio. 2014;5(2):e00912-00914.","journal-title":"MBio"},{"issue":"2","key":"2103_CR14","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.jinf.2012.03.020","volume":"65","author":"AD Punatar","year":"2012","unstructured":"Punatar AD, Kusne S, Blair JE, Seville MT, Vikram HR. Opportunistic infections in patients with pulmonary alveolar proteinosis. J Infect ao\u00fbt. 2012;65(2):173\u20139.","journal-title":"J Infect ao\u00fbt"},{"issue":"2","key":"2103_CR15","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1007\/s10875-011-9621-8","volume":"32","author":"L Ding","year":"2012","unstructured":"Ding L, Mo A, Jutivorakool K, Pancholi M, Holland SM, Browne SK. Determination of human anticytokine autoantibody profiles using a particle-based approach. J Clin Immunol avr. 2012;32(2):238\u201345.","journal-title":"J Clin Immunol avr"},{"issue":"4","key":"2103_CR16","doi-asserted-by":"publisher","first-page":"ofx211","DOI":"10.1093\/ofid\/ofx211","volume":"4","author":"NF Crum-Cianflone","year":"2017","unstructured":"Crum-Cianflone NF, Lam PV, Ross-Walker S, Rosen LB, Holland SM. Autoantibodies to granulocyte-macrophage colony-stimulating factor associated with severe and unusual manifestations of Cryptococcus gattii infections. Open Forum Infect Dis. 2017;4(4):ofx211.","journal-title":"Open Forum Infect Dis"},{"key":"2103_CR17","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.02733-18","author":"S ApplenClancey","year":"2019","unstructured":"ApplenClancey S, Ciccone EJ, Coelho MA, Davis J, Ding L, Betancourt R, et al. Cryptococcus deuterogattii VGIIa infection associated with travel to the pacific northwest outbreak region in an anti-granulocyte-macrophage colony-stimulating factor autoantibody-positive patient in the United States. MBio. 2019. https:\/\/doi.org\/10.1128\/mBio.02733-18.","journal-title":"MBio"},{"issue":"11","key":"2103_CR18","doi-asserted-by":"publisher","first-page":"5239","DOI":"10.1073\/pnas.92.11.5239","volume":"92","author":"K Bhol","year":"1995","unstructured":"Bhol K, Natarajan K, Nagarwalla N, Mohimen A, Aoki V, Ahmed AR. Correlation of peptide specificity and IgG subclass with pathogenic and nonpathogenic autoantibodies in pemphigus vulgaris: a model for autoimmunity. Proc Natl Acad Sci U S A. 1995;92(11):5239\u201343.","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"2","key":"2103_CR19","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.jim.2008.04.009","volume":"336","author":"J Gross","year":"2008","unstructured":"Gross J, Moller R, Bischoff S, Canaan-K\u00fchl S, Fromme M, Henke W. Detection and characterization of antibodies against recombinant human erythropoietin by RIPA, ELISA and neutralization assay in patients with renal anemia. J Immunol Methods. 2008;336(2):152\u20138.","journal-title":"J Immunol Methods"},{"issue":"3","key":"2103_CR20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0213179","volume":"14","author":"K Anderson","year":"2019","unstructured":"Anderson K, Carey B, Martin A, Roark C, Chalk C, Nowell-Bostic M, et al. Pulmonary alveolar proteinosis: an autoimmune disease lacking an HLA association. PLoS ONE. 2019;14(3): e0213179.","journal-title":"PLoS ONE"},{"issue":"1","key":"2103_CR21","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1038\/s41467-021-21011-y","volume":"12","author":"S Sakaue","year":"2021","unstructured":"Sakaue S, Yamaguchi E, Inoue Y, Takahashi M, Hirata J, Suzuki K, et al. Genetic determinants of risk in autoimmune pulmonary alveolar proteinosis. Nat Commun. 2021;12(1):1032.","journal-title":"Nat Commun."},{"issue":"3","key":"2103_CR22","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1136\/thorax.58.3.252","volume":"58","author":"JF Seymour","year":"2003","unstructured":"Seymour JF, Doyle IR, Nakata K, Presneill JJ, Schoch OD, Hamano E, et al. Relationship of anti-GM-CSF antibody concentration, surfactant protein A and B levels, and serum LDH to pulmonary parameters and response to GM-CSF therapy in patients with idiopathic alveolar proteinosis. Thorax. 2003;58(3):252\u20137.","journal-title":"Thorax"},{"issue":"6","key":"2103_CR23","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1136\/thx.2005.054171","volume":"61","author":"F-C Lin","year":"2006","unstructured":"Lin F-C, Chang G-D, Chern M-S, Chen Y-C, Chang S-C. Clinical significance of anti-GM-CSF antibodies in idiopathic pulmonary alveolar proteinosis. Thorax. 2006;61(6):528\u201334.","journal-title":"Thorax"},{"issue":"3","key":"2103_CR24","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1182\/blood-2003-05-1565","volume":"103","author":"K Uchida","year":"2004","unstructured":"Uchida K, Nakata K, Trapnell BC, Terakawa T, Hamano E, Mikami A, et al. High-affinity autoantibodies specifically eliminate granulocyte-macrophage colony-stimulating factor activity in the lungs of patients with idiopathic pulmonary alveolar proteinosis. Blood. 2004;103(3):1089\u201398.","journal-title":"Blood"},{"issue":"11","key":"2103_CR25","doi-asserted-by":"publisher","first-page":"2547","DOI":"10.1182\/blood-2008-05-155689","volume":"113","author":"K Uchida","year":"2009","unstructured":"Uchida K, Nakata K, Suzuki T, Luisetti M, Watanabe M, Koch DE, et al. Granulocyte\/macrophage-colony-stimulating factor autoantibodies and myeloid cell immune functions in healthy subjects. Blood. 2009;113(11):2547\u201356.","journal-title":"Blood"},{"issue":"1\u20132","key":"2103_CR26","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.jim.2013.11.011","volume":"402","author":"K Uchida","year":"2014","unstructured":"Uchida K, Nakata K, Carey B, Chalk C, Suzuki T, Sakagami T, et al. Standardized serum GM-CSF autoantibody testing for the routine clinical diagnosis of autoimmune pulmonary alveolar proteinosis. J Immunol Methods. 2014;402(1\u20132):57\u201370.","journal-title":"J Immunol Methods"},{"issue":"19","key":"2103_CR27","doi-asserted-by":"publisher","first-page":"7832","DOI":"10.1073\/pnas.1216011110","volume":"110","author":"Y Wang","year":"2013","unstructured":"Wang Y, Thomson CA, Allan LL, Jackson LM, Olson M, Hercus TR, et al. Characterization of pathogenic human monoclonal autoantibodies against GM-CSF. Proc Natl Acad Sci U S A. 2013;110(19):7832\u20137.","journal-title":"Proc Natl Acad Sci U S A."},{"key":"2103_CR28","doi-asserted-by":"publisher","first-page":"7375","DOI":"10.1038\/ncomms8375","volume":"6","author":"L Piccoli","year":"2015","unstructured":"Piccoli L, Campo I, Fregni CS, Rodriguez BMF, Minola A, Sallusto F, et al. Neutralization and clearance of GM-CSF by autoantibodies in pulmonary alveolar proteinosis. Nat Commun. 2015;6:7375.","journal-title":"Nat Commun."},{"issue":"2","key":"2103_CR29","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1042\/BJ20120884","volume":"447","author":"M Blech","year":"2012","unstructured":"Blech M, Seeliger D, Kistler B, Bauer MMT, Hafner M, H\u00f6rer S, et al. Molecular structure of human GM-CSF in complex with a disease-associated anti-human GM-CSF autoantibody and its potential biological implications. Biochem J. 2012;447(2):205\u201315.","journal-title":"Biochem J."},{"issue":"7","key":"2103_CR30","first-page":"1018","volume":"10","author":"U Dhagat","year":"2018","unstructured":"Dhagat U, Hercus TR, Broughton SE, Nero TL, CheungTungShing KS, Barry EF, et al. The mechanism of GM-CSF inhibition by human GM-CSF auto-antibodies suggests novel therapeutic opportunities. MAbs. 2018;10(7):1018\u201329.","journal-title":"MAbs"},{"issue":"1","key":"2103_CR31","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1080\/19420862.2015.1099774","volume":"8","author":"R Eylenstein","year":"2016","unstructured":"Eylenstein R, Weinfurtner D, H\u00e4rtle S, Strohner R, B\u00f6ttcher J, Augustin M, et al. Molecular basis of in vitro affinity maturation and functional evolution of a neutralizing anti-human GM-CSF antibody. MAbs. 2016;8(1):176\u201386.","journal-title":"MAbs"},{"issue":"1","key":"2103_CR32","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/nrrheum.2015.161","volume":"12","author":"IP Wicks","year":"2016","unstructured":"Wicks IP, Roberts AW. Targeting GM-CSF in inflammatory diseases. Nat Rev Rheumatol janv. 2016;12(1):37\u201348.","journal-title":"Nat Rev Rheumatol janv"},{"key":"2103_CR33","doi-asserted-by":"publisher","first-page":"225","DOI":"10.2147\/ITT.S262566","volume":"9","author":"KMC Lee","year":"2020","unstructured":"Lee KMC, Achuthan AA, Hamilton JA. GM-CSF: a promising target in inflammation and autoimmunity. ImmunoTargets Ther. 2020;9:225\u201340.","journal-title":"ImmunoTargets Ther"},{"issue":"2","key":"2103_CR34","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1093\/jalm\/jfz024","volume":"5","author":"S Ekici","year":"2020","unstructured":"Ekici S, Malur A, Thomassen MJ, Murray DL, Wylam ME. Utilization of LC-MS to determine monoclonal gammopathy-associated granulocyte macrophage colony stimulating factor antibody and novel treatment of pulmonary alveolar proteinosis. J Appl Lab Med. 2020;5(2):394\u2013400.","journal-title":"J Appl Lab Med."},{"issue":"1","key":"2103_CR35","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1186\/s12931-017-0613-y","volume":"18","author":"T Victoni","year":"2017","unstructured":"Victoni T, Salvator H, Abrial C, Brollo M, Porto LCS, Lagente V, et al. Human lung and monocyte-derived macrophages differ with regard to the effects of \u03b22-adrenoceptor agonists on cytokine release. Respir Res. 2017;18(1):126.","journal-title":"Respir Res"},{"key":"2103_CR36","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.pupt.2018.01.003","volume":"49","author":"E Naline","year":"2018","unstructured":"Naline E, Grassin Delyle S, Salvator H, Brollo M, Faisy C, Victoni T, et al. Comparison of the in vitro pharmacological profiles of long-acting muscarinic antagonists in human bronchus. Pulm Pharmacol Ther. 2018;49:46\u201353.","journal-title":"Pulm Pharmacol Ther"},{"issue":"12","key":"2103_CR37","doi-asserted-by":"publisher","first-page":"1908","DOI":"10.1016\/j.rmed.2011.08.018","volume":"105","author":"F Bonella","year":"2011","unstructured":"Bonella F, Bauer PC, Griese M, Ohshimo S, Guzman J, Costabel U. Pulmonary alveolar proteinosis: new insights from a single-center cohort of 70 patients. Respir Med d\u00e9c. 2011;105(12):1908\u201316.","journal-title":"Respir Med d\u00e9c"},{"issue":"1","key":"2103_CR38","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1186\/s12890-017-0493-4","volume":"17","author":"JA Hwang","year":"2017","unstructured":"Hwang JA, Song JH, Kim JH, Chung MP, Kim DS, Song JW, et al. Clinical significance of cigarette smoking and dust exposure in pulmonary alveolar proteinosis: a Korean national survey. BMC Pulm Med. 2017;17(1):147.","journal-title":"BMC Pulm Med."},{"issue":"11","key":"2103_CR39","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.1111\/imj.14637","volume":"49","author":"B Stevenson","year":"2019","unstructured":"Stevenson B, Bundell C, Mulrennan S, McLean-Tooke A, Murray R, Brusch A. The significance of anti-granulocyte-macrophage colony-stimulating factor antibodies in cryptococcal infection: case series and review of antibody testing. Intern Med J. 2019;49(11):1446\u201350.","journal-title":"Intern Med J"},{"key":"2103_CR40","doi-asserted-by":"publisher","first-page":"4601","DOI":"10.2147\/IDR.S249761","volume":"13","author":"E Lafont","year":"2020","unstructured":"Lafont E, Conan P-L, Rodriguez-Nava V, Lebeaux D. Invasive nocardiosis: disease presentation, diagnosis and treatment\u2014old questions, new answers? Infect Drug Resist. 2020;13:4601\u201313.","journal-title":"Infect Drug Resist"},{"issue":"2","key":"2103_CR41","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.immuni.2017.01.007","volume":"46","author":"S Spath","year":"2017","unstructured":"Spath S, Komuczki J, Hermann M, Pelczar P, Mair F, Schreiner B, et al. Dysregulation of the cytokine GM-CSF induces spontaneous phagocyte invasion and immunopathology in the central nervous system. Immunity. 2017;46(2):245\u201360.","journal-title":"Immunity"},{"issue":"2","key":"2103_CR42","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.immuni.2017.02.003","volume":"46","author":"J Zhao","year":"2017","unstructured":"Zhao J, Sun L, Li X. Commanding CNS invasion: GM-CSF. Immunity. 2017;46(2):165\u20137.","journal-title":"Immunity"},{"issue":"5","key":"2103_CR43","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1016\/j.immuni.2019.04.006","volume":"50","author":"J Komuczki","year":"2019","unstructured":"Komuczki J, Tuzlak S, Friebel E, Hartwig T, Spath S, Rosenstiel P, et al. Fate-mapping of GM-CSF expression identifies a discrete subset of inflammation-driving T helper cells regulated by cytokines IL-23 and IL-1\u03b2. Immunity. 2019;50(5):1289-1304.e6.","journal-title":"Immunity"}],"container-title":["Respiratory Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-022-02103-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12931-022-02103-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-022-02103-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,11]],"date-time":"2022-10-11T18:02:53Z","timestamp":1665511373000},"score":1,"resource":{"primary":{"URL":"https:\/\/respiratory-research.biomedcentral.com\/articles\/10.1186\/s12931-022-02103-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,11]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["2103"],"URL":"https:\/\/doi.org\/10.1186\/s12931-022-02103-9","relation":{},"ISSN":["1465-993X"],"issn-type":[{"value":"1465-993X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,11]]},"assertion":[{"value":"9 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 October 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent was provided by all participants or their guardians under appropriate IRB-approved protocols (07-I-0033, 93-I-0119, 93-I-0106, 95-I-0066).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable. The manuscript does not include any identifying images or other personal or clinical details of participants that could compromise anonymity.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors don\u2019t have any conflicts of interests to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"280"}}